Response criteria for glioma.

Nature Clinical Practice. Oncology
A Gregory SorensenRakesh K Jain

Abstract

The current method for assessing the response to therapy of glial tumors was described by Macdonald et al. in 1990. Under this paradigm, response categorization is determined on the basis of changes in the cross-sectional area of a tumor on neuroimaging, coupled with clinical assessment of neurological status and corticosteroid utilization. These categories of response have certain limitations; for example, cross-sectional assessment is not as accurate as volumetric assessment, which is now feasible. Disentangling antitumor effects of therapies from their effects on blood-brain barrier permeability can be challenging. The use of insufficient response criteria might be overestimating the true benefits of drugs in early-stage studies, and, therefore, such therapies could mistakenly move forward into later phases, only to result in disappointment when overall survival is measured. We propose that studies report both radiographic and clinical response rates, use volumetric rather than cross-sectional area to measure lesion size, and incorporate findings from mechanistic imaging and blood biomarker studies more frequently, and also suggest that investigators recognize the limitations of imaging biomarkers as surrogate end points.

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Oct 1, 1996·Annals of Internal Medicine·T R Fleming, D L DeMets
May 1, 1997·Neurology·R GrantL Junck
Jun 10, 1998·Current Opinion in Oncology·R S Kaplan
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A G SorensenR Weisskoff
Jun 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M Bagley
Sep 12, 2001·Neuro-oncology·K R HessW K Yung
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John R JohnsonRichard Pazdur
Jan 14, 2005·Health Affairs·Thomas R Fleming
May 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Andreas H JacobsKarl Herholz
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo BruzziMarco Venturini
Mar 2, 2006·Radiology·Thomas BennerA Gregory Sorensen
Mar 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas A ButowskiSusan M Chang
Dec 13, 2006·Nature Reviews. Drug Discovery·Alexander KambChristoph Lengauer
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J VredenburghHenry S Friedman

❮ Previous
Next ❯

Citations

Dec 2, 2008·Journal of Neuro-oncology·Andrew D NordenPatrick Y Wen
May 20, 2011·Current Treatment Options in Oncology·James FinkMarc C Chamberlain
Mar 27, 2013·Current Neurology and Neuroscience Reports·Olivier L ChinotTimothy F Cloughesy
Nov 19, 2010·Current Oncology Reports·Eudocia C Quant, Patrick Y Wen
Sep 16, 2010·Current Treatment Options in Neurology·Eudocia C QuantAndrew D Norden
May 21, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Nicholas Butowski
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew S ChiPatrick Y Wen
Jun 2, 2009·Nature Reviews. Clinical Oncology·Rakesh K JainA Gregory Sorensen
Jan 13, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J J C VerhoeffD J Richel
Feb 12, 2011·Neuro-oncology·David A ReardonPatrick Y Wen
Jun 4, 2011·Neuro-oncology·Wolfgang WickMichael Platten
Aug 13, 2011·Neuro-oncology·Fabio M IwamotoAdília Hormigo
Dec 18, 2009·BMC Cancer·Joost J C VerhoeffWouter R van Furth
Sep 29, 2011·Radiation Oncology·Adam GladwishCynthia Ménard
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walid S KamounRakesh K Jain
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J van den BentSusan M Chang
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christina TsienBrian D Ross
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy T BatchelorRakesh K Jain
Feb 8, 2011·PloS One·Charles W KanalyJohn H Sampson
Jan 1, 2009·OncoTargets and Therapy·Rimas V LukasM Kelly Nicholas
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Jul 24, 2014·CNS Oncology·Ana Xavier-MagalhãesBruno M Costa
Sep 1, 2014·Seminars in Oncology·Daniel TreisterMark S Shiroishi
Aug 21, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yong WangYaqun Zhao
Oct 15, 2014·Neuro-oncology·Benjamin M EllingsonTimothy F Cloughesy
Nov 16, 2011·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Roberto García FigueirasPeter L Choyke
May 25, 2012·The British Journal of Radiology·N Upadhyay, A D Waldman
May 25, 2012·The British Journal of Radiology·J H Rees
Mar 12, 2011·AJNR. American Journal of Neuroradiology·L C Hygino da CruzA G Sorensen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Patrick Y WenSusan M Chang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M J van den BentSusan M Chang
AJNR. American Journal of Neuroradiology
J W HensonG J Harris
© 2022 Meta ULC. All rights reserved